Emergence of new ALK mutations at relapse of neuroblastoma

Journal of Clinical Oncology

Volumn 32, Issue 25, 2014, Pages 2727-2734

  Schleiermacher, Gudrun ^a,b   Javanmardi, Niloufar ^f   Bernard, Virginie ^b   Leroy, Quentin ^b   Cappo, Julie ^a   Frio, Thomas Rio ^b   Pierron, Gaelle ^b   Lapouble, Eve ^b   Combaret, Valérie ^e   Speleman, Frank ^k   De Wilde, Bram ^k   Djos, Anna ^f   Øra, Ingrid ^g   Hedborg, Fredrik ^h   Träger, Catarina ⁱ   Holmqvist, Britt Marie ^j   Abrahamsson, Jonas ^f   Peuchmaur, Michel ^c,d   Michon, Jean ^b   Janoueix Lerosey, Isabelle ^a   Kogner, Per ⁱ   Delattre, Olivier ^a   Martinsson, Tommy ^f   more..

^a INSTITUT CURIE   (France)

^b INSTITUT CURIE   (France)

^c HÔPITAL ROBERT DEBRÉ   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e CENTRE LÉON BÉRARD   (France)

^f SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^g LUND UNIVERSITY   (Sweden)

^h UPPSALA UNIVERSITY   (Sweden)

ⁱ KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^j LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^k GHENT UNIVERSITY HOSPITAL   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALK RECEPTOR TYROSINE KINASE; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; ANAPLASTIC LYMPHOMA KINASE;

ARTICLE; BIOINFORMATICS; CANCER GENETICS; CANCER RECURRENCE; CELL POPULATION; CLONAL EVOLUTION; CONTROLLED STUDY; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; NEUROBLASTOMA; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; ADOLESCENT; ADULT; ENZYME ACTIVATION; ENZYMOLOGY; EXON; GENETICS; INFANT; MIDDLE AGED; POINT MUTATION; PRESCHOOL CHILD; TUMOR RECURRENCE; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED, 80 AND OVER; CHILD, PRESCHOOL; ENZYME ACTIVATION; EXONS; HUMANS; INFANT; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEUROBLASTOMA; POINT MUTATION; RECEPTOR PROTEIN-TYROSINE KINASES; YOUNG ADULT;

EID: 84906819212     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.54.0674     Document Type: Article

References (26)

1. Hanahan D, Weinberg RA: Hallmarks of cancer: The next generation. Cell 144:646-674, 2011
2. Ding L, Ley TJ, Larson DE, et al: Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 481: 506-510, 2012
3. Landau DA, Carter SL, Stojanov P, et al: Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 152:714-726, 2013
4. Schuh A, Becq J, Humphray S, et al: Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patterns. Blood 120:4191-4196, 2012
5. Welch JS, Ley TJ, Link DC, et al: The origin and evolution of mutations in acute myeloid leukemia. Cell 150:264-278, 2012
6. Maris JM, Hogarty MD, Bagatell R, et al: Neuroblastoma. Lancet 369:2106-2120, 2007
7. Janoueix-Lerosey I, Schleiermacher G, Michels E, et al: Overall genomic pattern is a predictor of outcome in neuroblastoma. J Clin Oncol 27:1026-1033, 2009
8. Molenaar JJ, Koster J, Zwijnenburg DA, et al: Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature 483:589-593, 2012
9. Pugh TJ, Morozova O, Attiyeh EF, et al: The genetic landscape of high-risk neuroblastoma. Nat Genet 45:279-284, 2013
10. Sausen M, Leary RJ, Jones S, et al: Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. Nat Genet 45:12-17, 2013
11. Schleiermacher G, Janoueix-Lerosey I, Ribeiro A, et al: Accumulation of segmental alterations determines progression in neuroblastoma. J Clin Oncol 28:3122-3130, 2010
12. Carén H, Abel F, Kogner P, et al: High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours. Biochem J 416:153-159, 2008
13. De Brouwer S, De Preter K, Kumps C, et al: Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification. Clin Cancer Res 16:4353-4362, 2010
14. Hallberg B, Palmer RH: Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology. Nat Rev Cancer 13:685-700, 2013
15. Janoueix-Lerosey I, Lequin D, Brugieres L, et al: Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 455: 967-970, 2008
16. Mossé YP, Laudenslager M, Longo L, et al: Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 455:930-935, 2008
17. Schulte JH, Lindner S, Bohrer A, et al: MYCN and ALKF1174L are sufficient to drive neuroblastoma development from neural crest progenitor cells. Oncogene 32:1059-1065, 2013
18. Barone G, Anderson J, Pearson AD, et al: New strategies in neuroblastoma: Therapeutic targeting of MYCN and ALK. Clin Cancer Res 19:5814-5821, 2013
19. Bresler SC, Wood AC, Haglund EA, et al: Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma. Sci Transl Med 3:108ra114, 2011
20. Carpenter EL, Mossé YP: Targeting ALK in neuroblastoma: Preclinical and clinical advancements. Nat Rev Clin Oncol 9:391-399, 2012
21. Mossé YP, Lim MS, Voss SD, et al: Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic largecell lymphoma: A Children's Oncology Group phase 1 consortium study. Lancet Oncol 14:472-480, 2013
22. Martinsson T, Eriksson T, Abrahamsson J, et al: Appearance of the novel activating F1174S ALK mutation in neuroblastoma correlates with aggressive tumor progression and unresponsiveness to therapy. Cancer Res 71:98-105, 2011
23. Ihle MA, Fassunke J, Konig K, et al: Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations. BMC Cancer 14:13, 2014
24. Monzon FA, Ogino S, Hammond ME, et al: The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer. Arch Pathol Lab Med 133:1600-1606, 2009
25. Liu L, Li Y, Li S, et al: Comparison of nextgeneration sequencing systems. J Biomed Biotechnol 2012:251364, 2012
26. Ross MG, Russ C, Costello M, et al: Characterizing and measuring bias in sequence data. Genome Biol 14:R51, 2013